AstraZeneca Announces Voluntary Delisting from Nasdaq and Direct Listing on NYSE

On January 20, AstraZeneca announced its voluntary delisting of American Depositary Shares (ADS) and debt securities issued by the company or its wholly-owned subsidiaries and guaranteed by the company from The NASDAQ Stock Market LLC.

At the same time, AstraZeneca plans to transfer its common stock and debt securities to the New York Stock Exchange for a direct listing. This change is expected to take effect officially after the market closes on January 30, 2026. The direct listing plan has been approved by the company's shareholders.

AstraZeneca's common stock and debt securities will begin trading on the New York Stock Exchange on Monday, February 2, 2026. The trading code will remain unchanged as "AZN".

After the adjustment is completed, AstraZeneca shares will achieve interconnected trading across the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange, allowing investors to directly trade common shares in these three markets without the need for conversion through depositary receipts.

Recently, AstraZeneca has been making continuous moves. Earlier, on January 16, 2026, CBMG Biotech announced an agreement with AstraZeneca, under which AstraZeneca will acquire a 50% share of CBMG's development and commercialization rights for C-CAR031 in China. As a result, AstraZeneca will obtain exclusive global rights for the development, production, and commercialization of C-CAR031.

According to the terms of the agreement, CBMG will be entitled to receive up to $630 million from AstraZeneca, including an upfront payment for the GPC3 project in China as well as development, regulatory, and sales milestone payments.